GlassScriptPhysician profile
Kevin Watson
NPI 1790006997
$10,289.95
in general payments reported to CMS, 2019-2025
19 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $4,055 · 2021: $169 · 2022: $311 · 2023: $2,792 · 2024: $2,349 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $2,000 · Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $2,000.00 |
| Food and Beverage | $1,566.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $8,561.80 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $429.58 | 2019-2025 | |
| Echosens North America, INC. | $429.27 | 2023 | Fibroscan |
| Genzyme Corporation | $282.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.01 | 2021-2025 | Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $64.84 | 2023-2024 | Linzess |
| Mirum Pharmaceuticals, INC. | $59.55 | 2022-2025 | Livmarli, Cholbam, Chenodal |
| Ipsen Biopharmaceuticals, INC | $41.52 | 2023-2025 | Bylvay |
| Regeneron Healthcare Solutions, INC. | $39.53 | 2022-2023 | Dupixent |
| Avanos Medical | $38.67 | 2024-2025 | Mic-Key, Endoscopy |
| Neuraxis, INC. | $37.24 | 2022 | |
| Alcresta Therapeutics, INC. | $28.41 | 2025 | Relizorb |
| Janssen Biotech, INC. | $21.80 | 2024 | Simponi, Stelara, Tremfya |
| Amgen INC. | $17.76 | 2023 | Amjevita |
| Pharming Healthcare, INC. | $17.16 | 2023 | Ruconest |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.23 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.78 | 2023 | |
| Travere Therapeutics, INC. | $11.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.